RECOMBINANT IL-2 AND B-INTERFERON IN LYMPHOMA

重组 IL-2 和 B-干扰素治疗淋巴瘤

• 批准号: 3905567
• 负责人: DAVID B DUGGAN
• 金额: --
• 依托单位: UPSTATE MEDICAL UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3905567
• 关键词: combination cancer therapy; human subject; human therapy evaluation; interferons; interleukin 2; lymphoma; neoplasm /cancer immunotherapy; neoplasm /cancer relapse /recurrence

The study objectives include determining the efficacy of IL-2 and b-IFN + IL-2, as well as evaluating toxicity for patients with relapsed or refractory non-Hodgkin's Lymphoma. The hypothesis that there may be antiviral, antiproliferative, and immuno-modulating synergism between IL-2 and b-IFN will be uder investigation. The effect of IL-2 alone and in combination with b-IFN on in-vivo activation of NK and LAK cells will be assessed and NK and activation with tumor rresponse to therapy will be correlated.

研究目的包括确定IL-2和b-IFN的疗效 + IL-2，以及评估复发或复发患者的毒性。 难治性非霍奇金淋巴瘤假设可能有 抗病毒、抗增殖和免疫调节协同作用， IL-2和b-干扰素将作为研究对象。IL-2单独和 与b-IFN组合对NK和LAK细胞体内活化作用将 将评估NK和活化与肿瘤对治疗的反应， 是相关的。